New Rutgers saliva test for coronavirus gets FDA approval

Emergency use authorization granted for new biomaterial collection approachRutgers UniversityIMAGE: Rutgers Professor Andrew Brooks, chief operating officer and director of technology development at RUCDR Infinite Biologics.viewmore Credit: Rutgers University The FDA has granted emergency use authorization (EUA) to Rutgers 'RUCDR Infinite Biologics and its collaborators for a new collection approach that utilizes saliva as the primary test biomaterial for the SARS-CoV-2 coronavirus, the first such approval granted by the federal agency. The new saliva collection method, which RUCDR developed in partnership with Spectrum Solutions and Accurate Diagnostic Labs (ADL), will allow for broader population screening than the current method of nose and throat swabs." The impact of this approval is significant, " saidAndrew Brooks, chief operating officer and director of technology development at RUCDR, who also is a professor in theSchool of Arts and SciencesDepartment of Genetics atRutgers University-New Brunswick. " It means we no longer have to put health care professionals at risk for infection by performing nasopharyngeal or oropharyngeal collections. We can preserve precious personal protective equipment for use in patient care instead of testing. We can significantly increase the number of people tested each and every day as self-collection of saliva is more quick and scalable than swab collections. All of this combined will have a tremendous impact on testing in New ...
Source: Dental Technology Blog - Category: Dentistry Source Type: news